Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (9015)	9/1/2003 5:01:10 PM
From: Icebrg	Read Replies (2) \| Respond to of 52153

The optimum time for drug licensing James Kalamas & Gary Pinkus James Kalamas is a Principal and Gary Pinkus a Director in the Pharmaceutical and Medical Products Practice, McKinsey & Company, 555 California Street, Suite 4700, San Francisco, California 94104, USA. james_kalamas@mckinsey.com gary_pinkus@mckinsey.com As the fortunes of 'big pharma' and the biotech industry become inextricably linked, effective drug licensing is becoming increasingly important. For the pharmaceutical industry, innovative biotech compounds have served to buttress lagging R&D productivity; whereas for biotech, partnerships with pharma have provided a stable source of much needed capital in the face of volatile public markets. In addition, pharma brings clinical development, portfolio management and commercialization skills that are lacking in many biotech companies. The optimal timing for drug licensing is an important strategic question, and the general view in both pharma and biotech is that the right time for these deals is during Phase II clinical development, although most deals take place sometime between preclinical and Phase II development. However, our analysis shows that pharma and biotech could create more value for themselves by doing deals earlier. To realize this value, both parties will need to change their approaches to drug licensing — both internally and in their dealings with potential partners.... nature.com